REGENXBIO INC. DL-,0001 WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0 Forum: Aktien Thema: Hauptdiskussion
14,65 EUR
-2,33 %-0,35
25. Apr, 15:49:36 Uhr,
L&S Exchange
Kommentare 84
Summer.76,
16.07.2021 21:49 Uhr
0
REGENXBIO and Abeona update on arbitration of licensing dispute
https://seekingalpha.com/news/3716050-regenxbio-and-abeona-update-on-arbitration-of-licensing-dispute
Summer.76,
14.05.2021 14:09 Uhr
0
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting
https://www.prnewswire.com/news-releases/regenxbio-presents-additional-positive-interim-data-from-phase-iii-trial-of-rgx-121-for-the-treatment-of-mps-ii-hunter-syndrome-at-american-society-of-gene-and-cell-therapys-24th-annual-meeting-301291376.html
• RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events
• Biomarkers and measures of neurodevelopmental function from patients in Cohorts 1 and 2 continue to indicate CNS activity following RGX-121 administration
• Evidence of systemic enzyme expression and biomarker activity continues to be observed
• REGENXBIO recently initiated dosing of patients in Cohort 3
...
Summer.76,
05.05.2021 22:34 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-reports-first-quarter-2021-financial-results-and-operational-highlights-301284916.html
Summer.76,
15.04.2021 5:30 Uhr
0
REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome)
https://www.prnewswire.com/news-releases/regenxbio-announces-dosing-of-first-patient-in-cohort-3-of-phase-iii-trial-of-rgx-121-for-the-treatment-of-mps-ii-hunter-syndrome-301269209.html
• First patient dosed at third dose level in ongoing trial of RGX-121, a one-time gene therapy for MPS II; total of nine patients have been dosed at four leading clinical centers in the U.S. and Brazil
• Previously reported positive interim data from Cohorts 1 and 2 demonstrated consistent reductions in CNS biomarkers, continued neurocognitive development, and evidence of systemic effects
...
Summer.76,
01.03.2021 22:26 Uhr
0
Regenxbio: 4Q Earnings Snapshot
https://www.sfchronicle.com/business/article/Regenxbio-4Q-Earnings-Snapshot-15990371.php
REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights
https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-and-full-year-2020-financial-results-and-operational-highlights-301237754.html
Summer.76,
16.02.2021 13:50 Uhr
0
REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD
https://www.prnewswire.com/news-releases/regenxbio-announces-additional-positive-interim-phase-iiia-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd-301228344.html
...
Summer.76,
09.02.2021 20:40 Uhr
0
REGENXBIO patent case may weigh on Sarepta, according to Morgan Stanley
https://seekingalpha.com/news/3660139-regenxbio-patent-case-may-weigh-on-sarepta-according-to-morgan-stanley
• Morgan Stanley analyst Matthew Harrison writes that a patent case filed by REGENXBIO Inc. (NASDAQ:RGNX) against Sarepta Therapeutics (NASDAQ:SRPT) regarding SRP-9001 and SRP-9003 could have implications for the company.
• In late December, a federal judge denied a motion from Sarepta Therpeutics (SRPT) to dismiss a lawsuit filed by Wilson Wolf Manufacturing Corp. regarding SRP-9001.
• Harrison notes that REGENEXBIO "may be able to obtain a higher royalty based on its AAV patent (a mid-to-high single-digit royalty) than Wilson Wolf can likely obtain based on its cell-culture-device patent (a low single-digit royalty)."
• Sarepta has also filed a motion to dismiss the REGENXBIO case.
• Harrison maintains an equal-weight rating on the stock and a $95 price target.
JeromePower,
03.02.2021 21:04 Uhr
0
🎯
Summer.76,
13.01.2021 6:04 Uhr
0
https://www.wfmz.com/news/pr_newswire/pr_newswire_business/regenxbio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option/article_face8711-b686-5c26-b70e-60d65205afa4.html
Summer.76,
07.01.2021 5:06 Uhr
0
REGENXBIO Announces Proposed Public Offering Of Common Stock
https://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-301202287.html
Summer.76,
06.01.2021 5:18 Uhr
0
REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
https://www.prnewswire.com/news-releases/regenxbio-announces-update-on-rgx-314-and-pivotal-program-for-the-treatment-of-wet-amd-and-new-gene-therapy-program-for-the-treatment-of-duchenne-muscular-dystrophy-301201378.html
Summer.76,
22.12.2020 22:39 Uhr
0
REGENXBIO Announces Agreement to Monetize Portion of Zolgensma Royalties for $200 Million
https://www.prnewswire.com/news-releases/regenxbio-announces-agreement-to-monetize-portion-of-zolgensma-royalties-for-200-million-301197818.html
Agreement with Healthcare Royalty enables REGENXBIO to advance its broad gene therapy pipeline, including pivotal program for RGX-314
...
Summer.76,
19.12.2020 16:04 Uhr
0
Regenxbio: Championing Gene Therapy
https://seekingalpha.com/article/4395464-regenxbio-championing-gene-therapy
Summer.76,
10.12.2020 13:31 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-announces-dosing-of-first-patient-in-phase-ii-altitude-trial-of-rgx-314-for-the-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery-301190019.html
Summer.76,
09.12.2020 13:29 Uhr
0
REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II
https://www.prnewswire.com/news-releases/regenxbio-announces-positive-interim-data-and-update-for-phase-iii-trial-of-rgx-121-for-the-treatment-of-mps-ii-301189001.html
- Consistent reductions in CSF levels of heparan sulfate up to 2 years after administration, as well as continued developmental skill acquisition
- Initial data from Cohort 2 indicates evidence of systemic enzyme expression and biomarker activity
- Additional data from Cohorts 1 and 2 to be presented at WORLDSymposium in February 2021
- REGENXBIO expects to initiate dosing of patients in Cohort 3 at an increased dose in the first quarter of 2021
...
Summer.76,
04.11.2020 22:19 Uhr
0
Regenxbio EPS beats by $1.14, beats on revenue
https://seekingalpha.com/news/3631476-regenxbio-eps-beats-1_14-beats-on-revenue
Regenxbio (NASDAQ:RGNX): Q3 GAAP EPS of $0.24 beats by $1.14.
Revenue of $98.9M (+572.8% Y/Y) beats by $74.1M.
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | EVOTEC Hauptdiskussion | -4,95 % | |
2 | Meta Platforms Hauptdiskussion | -13,84 % | |
3 | für alle, die es ehrlich meinen beim Traden. | ||
4 | Das neue Dax Prognose Forum | -1,48 % | |
5 | AIXTRON Hauptdiskussion | -4,76 % | |
6 | TESLA MOTORS Hauptdiskussion | +1,14 % | |
7 | DAX Hauptdiskussion | -1,48 % | |
8 | SUPER MICRO Hauptdiskussion | -0,54 % | |
9 | NVIDIA Hauptdiskussion | +1,66 % | |
10 | Jaguar Health für Investierte und Interessierte | -5,34 % | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | EVOTEC Hauptdiskussion | -4,41 % | |
2 | Meta Platforms Hauptdiskussion | -2,83 % | |
3 | AIXTRON Hauptdiskussion | -4,33 % | |
4 | TESLA MOTORS Hauptdiskussion | +1,02 % | |
5 | SUPER MICRO Hauptdiskussion | +2,58 % | |
6 | Jaguar Health für Investierte und Interessierte | -5,34 % | |
7 | NVIDIA Hauptdiskussion | +1,49 % | |
8 | PLUG POWER Hauptdiskussion | -6,32 % | |
9 | PAYPAL Hauptdiskussion | -2,22 % | |
10 | Hauptdiskussion über TUI Aktie | -0,79 % | Alle Diskussionen |